This retrospective real-world cohort study analyzed data from the TriNetX global research network, including 459,886 adults with T2DM or obesity who initiated tirzepatide or alternative GLP-1 RAs
Advertencia Regulatoria: Este producto se suministra exclusivamente para fines de investigacin y desarrollo (I+D)
Meehan CA, Cochran E, Kassai A, Brown RJ, Gorden P
le Roux, [email protected] Disclaimer All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers
However, significant weight loss may reduce thyroid hormone requirements, potentially necessitating levothyroxine dose adjustments as patients lose weight